Artificial cells for replacement of metabolic organ functions

Artificial Cells, Blood Substitutes, and Immobilization Biotechnology

Volumn 31, Issue 2, 2003, Pages 151-161

  Chang, Thomas Ming Swi ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

Artificial cells; Bioencapsulation; Blood substitutes; Cell therapy; Enzyme therapy; Gene therapy; Hybrid artificial organs; Kidney support; Liver support

Indexed keywords

BIOTECHNOLOGY; CHARCOAL; DISEASES; ENZYMES; GENETIC ENGINEERING;

ARTIFICIAL CELLS;

CELLS;

ACTIVATED CARBON; CELL ENZYME; HEMOGLOBIN;

ADOPTIVE IMMUNOTHERAPY; ARTIFICIAL ORGAN; BIOTECHNOLOGY; BLOOD SUBSTITUTION; CELL ENCAPSULATION; CELL FUNCTION; CHEMICAL ENGINEERING; CONFERENCE PAPER; DIABETES MELLITUS; ENZYME DEFICIENCY; GENE THERAPY; GENETIC ENGINEERING; HEMOPERFUSION; HUMAN; IMPLANTATION; KIDNEY FAILURE; LIVER FAILURE; SUBSTITUTION THERAPY;

ARTIFICIAL ORGANS; BLOOD SUBSTITUTES; HUMANS; INFUSION PUMPS, IMPLANTABLE; METABOLISM, INBORN ERRORS; TISSUE ENGINEERING;

EID: 0037989843     PISSN: 10731199     EISSN: None     Source Type: Journal    
DOI: 10.1081/BIO-120020173     Document Type: Conference Paper

References (69)

1. Adamson, J. G., Moore, C. (1998). Hemolink™, an o-Raffinose crosslinked hemoglobin-based oxygen carrier. In: Chang, T. M. S., ed. Blood Substitutes: Principles, Methods, Products and Clinical Trials. Vol. 2. Basel: Karger, 62-79.
2. Aebischer, P., Schluep, M., Deglon, N., Joseph, J. M., Hirt, L., Heyd, B., Goddard, M., Hammang, J. P., Zurn, A. D., Kato, A. C., Regli, F., Baetge, E. E. (1996). Intrathecal delivery of CNTF using encapsulated genetically modified xenogeneic cells in amyotrophic lateral sclerosis patients. Nat. Med. 2:696-699.
3. Bourget, L., Chang, T. M. S. (1986). Phenylalanine ammonia-lyase immobilized in microcapsules for the depleture of phenylalanine in plasma in phenylketonuric rat model. Biochim. Biophys. Acta. 883:432-438.
4. Bruni, S., Chang, T. M. S. (1989). Hepatocytes immobilized by microencapsulation in artificial cells: effects on hyperbiliru-binemia in Gunn Rats. J. Biomat. Artif. Cells Artif. Organs 17:403-412.
5. Bunn, H. F., Jandl, J. H. (1968). The renal handling of hemoglobin. Trans. Assoc. Am. Physicians 81:147.
6. Chang, T. M. S. (1964). Semipermeable microcapsules. Science 146:524-525.
7. Chang, T. M. S. (1966). Semipermeable aqueous microcapsules ["artificial cells"]: with emphasis on experiments in an extracorporeal shunt system. Trans. Am. Soc. Artif. Intern. Organs. 12:13-19.
8. Chang, T. M. S. (1971a). The in vivo effects of semipermeable microcapsules containing L-asparaginase on 6C3HED lymphosarcoma. Nature 229 (528):117-118.
9. Chang, T. M. S. (1971b). Stabilization of enzyme by microencapsulation with a concentrated protein solution or by crosslinking with glutaraldehyde. Biochem. Biophys. Res. Commun. 44:1531-1533.
10. Chang, T. M. S. (1972). Artificial Cells. Springfield: C.C., Thomas Publisher.
11. Chang, T. M. S. (1975). Microencapsulated adsorbent hemoperfusion for uremia, intoxication and hepatic failure. Kidney Int. 7:S387-S392.
12. Chang, T. M. S. (1995). Artificial cells with emphasis on bioencapsulation in biotechnology. Biotechnol. Ann. Rev. 1:267-295.
13. Chang, T. M. S. (1997a). In: Dulbecco, R., ed. Artificial Cells "Encyclopedia of Human Biology." 2nd ed. San Diego: Academic Press, CA, pp. 457-463.
14. Chang, T. M. S. (1997b). Live E. coli cells to treatment uremia: replies to letters to the editor. Nat. Med. 3:2-3.
15. Chang, T. M. S. (1997c). Blood Substitutes: Principles, Methods, Products and Clinical Trials. Vol. 1. Basel: Karger.
16. Chang, T. M. S. (1999). Artificial blood: a prospective. Trends Biotechnol. 17:61-67.
17. Chang, T. M. S. (2000). Is there a need for blood substitutes in the new millennium and what can we expect in the way of safety and efficacy. Artif. Cells Blood Substit. Immobil. Biotechnol. 28(1):i-vii. an international journal.
18. Chang, T. M. S. (2001). Bioencapsulated hepatocytes for experimental liver support. J. Hepatol. 34:148-149.
19. Chang, T. M. S. (2002). Oxygen carriers. Curr. Opin. Invest. Drugs 3 (8):1187-1190.
20. Chang, T. M. S., Poznansky, M. J. (1968). Semipermeable microcapsules containing catalase for enzyme replacement in acatalsaemic mice. Nature 218(5138):242-245.
21. Chang, T. M. S., Prakash, S. (1998). Therapeutic uses of microencapsulated genetically engineered cells. Mol. Med. Today 4:221-227.
22. Chang, T. M. S., Prakash, S. (2001a). Procedure for microencapsulationof enzymes, cells and genetically engineered microorganisms. Mol. Biotechnol. 17:249-260.
23. Chang, T. M. S., Prakash, S. (2001b). Microencapsulated Genetically Engineered Microorganisms for Clinical Application. U.S. Patent 6,217,859, April 17, 2001.
24. Chang, T. M. S., Prakash, S. (2001c). Microencapsulated Genetically Engineered Microorganisms for Clinical Application. Japanese Patent 3228941, September 7, 2001.
25. Chang, T. M. S., Wong, H. (1992). A Novel Method for Cell Encapsulation in Artificial Cells. USA Patent No. 5,084,350, Issued Jan. 28, 1992.
26. Chang, T. M. S., Yu, W. P. (1997). Biodegradable Polymer Membrane Containing Hemoglobin for Blood Substitutes. U.S.A. Patent 5670173, September 23, 1997.
27. Chang, T. M. S., Yu, W. P. (1998). Nanoencapsulation of hemoglobin and red blood cell enzymes based on nanotechnology and biodegradable polymer. In: Chang, T. M. S., ed. Blood Substitutes: Principles, Methods, Products and Clinical Trials. Vol. 2. Basel: Karger, pp. 216-231.
28. Chang, T. M. S., Yu, B. (2002). Composition for inhibiting tumour growth and methods thereof. US Provisional Patent Application 60/364,581, March 18, 2002.
29. Chang, T. M. S., MacIntosh, F. C., Mason, S. G. (1966). Semipermeable aqueous microcapsules: I. Preparation and properties. Can. J. Physiol. Pharm. 44:115-128.
30. Chang, T. M. S., Bourget, L., Lister, C. (1995). New theory of enterorecirculation of amino acids and its use for depleting unwanted amino acids using oral enzyme-artificial cells, as in removing phenylalanine in phenylketonuria. Artif. Cells Blood Substit. Immobil. Biotechnol. 25:1-23.
31. Chang, T. M. S., Powanda, D., Yu, W. P. (2002). Biodegradable Polymeric Nanocapsules and Uses Thereof. PCT.
32. D'Agnillo, F., Chang, T. M. S. (1997). Modified Hemoglobin Blood Substitute from Cross-Linked Hemoglobin-Superoxide Dismutase-Catalase. US Patent 5,606,025, Feb. 1997.
33. D'Agnillo, F., Chang, T. M. S. (1998a). Polyhemoglobin-superoxide dismutase, catalase as a blood substitute with antioxidant properties. Nat. Biotechnol. 16(7):667-671.
34. D'Agnillo, F., Chang, T. M. S. (1998b). Absence of hemoprotein-associated free radical events following oxidant challenge of crosslinked hemoglobin-superoxide dismutase-catalase. Free Radic. Biol. Med. 24(6):906-912.
35. Dionne, K. E., Cain, B. M., Li, R. H., Bell, W. J., Doherty, E. J., Rein, D. H., Lysaght, M. J., Gentile, F. T. (1996). Transport characterization of membranes for immunoisolation. Biomaterials 17:257-266.
36. Djordjevich, L., Miller, I. F. (1980). Synthetic erythrocytes from lipid encapsulated hemoglobin. Exp. Hematol. 8:584.
37. Doherty, D. H., Doyle, M. P., Curry, S. R., Vali, R. J., Fattor, T. J., Olson, J. S., Lemon, D. D. (1998). Rate of reaction with nitric oxide determines the hypertensive effect of cell-free hemoglobin. Nat. Biotechnol. 16:672-676.
38. Dudziak, R., Bonhard, K. (1980). The development of hemoglobin preparations for various indications. Anesthesist 29:181-187.
39. Freytag, J. W., Templeton, D. (1997). Optro™ [Recombinant human hemoglobin]: a therapeutic for the delivery of oxygen and the restoration of blood volume in the treatment of acute blood loss in trauma and surgery. In: Rudolph, A. S., Rabinovici, R., Feuerstein, G. Z., eds. New York: Marcel Dekker, Inc, pp. 325-334.
40. Gould, S. A., Moore, F. A. (1998). The first randomized tiral of Human polymerized hemoglobin as a blood stubstitute in acute trauma and emergent surgery. J. Am. Coll. Surg. 187:113-120.
41. Gould, S. A., Sehgal, L. R., Sehgal, H. L., DeWoskin, R., Moss, G. S. (1998). The clinical development of human polymerized hemoglobin. In: Chang, T. M.S., ed. Blood Substitutes: Principles, Methods, Products and Clinical Trials. Vol. 2. Basel: Karger, pp. 12-28.
42. Hoffman, S. J., Looker, D. L., Roehrich, J. M. Expression of fully functional tetrameric human hemoglobin in Escherichia coli. Proc. Natl. Acad. Sci. U. S. A. 87:8521-8525.
43. Hunkeler, D., Prokop, A., Cherrington, A. D., Rajotte, R., Sefton, M., eds. Bioartificial Organs: Technology Medicine and Material. Ann. N.Y. Acad. Sci. Acad. Sci, 831: 271-279.
44. Kulitreibez, W. M., Lauza, P. P., Cuicks, W. L., eds. (1999). Cell Encapsulation Technology and Therapy. Boston: Burkhauser.
45. Lim, F., Sun, A. M. (1980). Microencapsulated islets as bioartificial endocrine pancreas. Science 210:908-909.
46. Liu, Z., Chang, T. M. S. (2000). Effects of bone marrow cells on hepatocytes: when co-cultured or co-encapsulated together. Artif. Cells Blood Substit. Immobil. Biotechnol. 28(4):365-374. an international journal.
47. Liu, Z. C., Chang, T. M. S. (2002). Transplantation of co-encapsulated hepatocytes and marrow stem cells into rats. Artif. Cells Blood Substit. Immobil. Biotechnol. 30:99-112. an international journal.
48. Liu, J., Jia, X., Zhang, J., Xiang, G., Hu, W., Zhou, Y. (2002). Study on a novel strategy to treatment of Phenylketonuria. Artif. Cells Blood Substit. Immobil. Biotechnol. 30:243-258.
49. Nelson, D. J. (1998). Blood and HemAssist™ [DCLHb]: potentially a complementary therapeutic team. In: Chang, T. M. S., ed. Blood Substitutes: Principles, Methods, Products and Clinical Trials. Vol. 2. Basel: Karger, pp. 39-57.
50. Orive, G., Hernandez, R. M., Gascon, A. R., Calafiore, R., Chang, T. M. S. (2003). Cell encapsulation: promise and progress. Nat. Med. 9:104-107.
51. Palmour, R. M., Goodyer, P., Reade, T., Chang, T. M. S. (1989). Microencapsulated xanthine oxidase as experimental therapy in Lesch-Nyhan Disease. Lancet 2(8664):687-688.
52. Pearce, L. B., Gawryl, M. S. (1998). Overview of preclinical and clinical efficacy of biopure's HBOCs. In: Chang, T. M. S., ed. Blood Substitutes: Principles, Methods, Products and Clinical Trials. Vol. 2. Basel: Karger, pp. 82-98.
53. Philips, W. T., Klpper, R. W., Awasthi, V. D., Rudolph, A. S., Cliff, R., Kwasiborski, V. V., Goins, B. A. (1999). Polyethylene glyco-modified liposome-encapsulated hemoglobin: a long circulating red cell substitute. J. Pharmacol. Exp. Ther. 288:665-670.
54. Powanda, D., Chang, T. M. S. (2002). Cross-linked polyhemoglobin- superoxide dismutase-catalase supplies oxygen without causing blood brain barrier disruption or brain edema in a rat model of transient global brain ischemia-reperfusion. Artif. Cells Blood Substit. Immobil. Biotechnol. 30:25-42. an international journal.
55. Poznansky, M. J., Chang, T. M. S. (1974). Comparison of the enzyme kinetics and immunological properties of catalase immobilized by microencapsulation and catalase in free solution for enzyme replacement. Biochim. Biophys. Acta. 334:103-115.
56. Prakash, S., Chang, T. M. S. (1996). Microencapsulated genetically Engineered live E. coli DH5 cells administered orally to maintain normal plasma urea level in uremic rats. Nat. Med. 2(8):883-887.
57. Prakash, S., Chang, T. M. S. (1999). Growth kinetics of genetically engineered E. coli dh 5 cells in artificial cell APA membrane microcapsules: preliminary report. Artif. Cells Blood Substit. Immobil. Biotechnol. 27(3):291-301. an international journal.
58. Razack, S., D'Agnillo, F., Chang, T. M. S. (1997). Effects of polyhemoglobin-catalase-superoxide dismutase on oxygen radicals in an ischemiareperfusion rat intestinal model. Artif. Cells Blood Substit. Immobil. Biotechnol. 25:181-192.
59. Rudolph, A. S., Rabinovici, R., Feuerstein, G. Z., eds. (1997). Red Blood Cell Substitutes. New York: Marcel Dekker, Inc.
60. Sarkissian, C. N., Shao, Z., Blain, F., Peevers, R., Su, H., Heft, R., Chang, T. M. S., Scriver, C. R. (1999). A different approach to treatment of phenylketonuria: phenylalanine degradation with recombinant phenylalanine ammonia lyase. Proc. Natl. Acad. Sci. 96:2339-2344.
61. Tsuchida, E., ed. (1998). Blood Substitutes: Present and Future Perspectives. Amsterdam: Elservier.
62. Winchester, J. F. (1988). Hemoperfusion. In: Maher, J. F., ed. Replacement_of_Renal Function by Dialysis. Boston: Kluwer Academic, pp. 439-592.
63. Winslow, R. M., Vandegriff, K. D., Intaglietta, M., eds. (1997). Blood Substitutes: Industrial Opportunities and Medical Challenges. Boston: Birkhauser.
64. Wong, H., Chang, T. M. S. (1986). Bioartificial liver: implanted artificial cells microencapsulated living hepatocytes increases survival of liver failure rats. Int. J. Artif. Organs 9:335-336.
65. Wong, H., Chang, T. M. S. (1988). The viability and regeneration of artificial cell microencapsulated rat hepatocyte xenograft transplants in mice. J. Biomat. Artif. Cells Artif. Organs 16:731-740.
66. Wong, H., Chang, T. M. S. (1991a). Microencapsulation of cells within alginate poly-L-lysine microcapsules prepared with standard single step drop technique: histologically identified membrane imperfections and the associated graft rejection. Biomater. Artif. Cells Immobil. Biotechnol. 19:675-686.
67. Wong, H., Chang, T. M. S. (1991b). A novel two-step procedure for immobilizing living cells in microcapsule for improving xenograft survival. Biomater. Artif. Cells Immobil. Biotechnol. 19:687-698.
68. Yu, W. P., Chang, T. M. S. (1996). Submicron polymer membrane hemoglobin nanocapsules as potential blood substitutes: preparation and characterization. Artif. Cells Blood Substit. Immobil. Biotechnol. 24:169-184. an international journal.
69. Yu, B. L., Chang, T. M. S. (2002). In-vitro kinetics of encapsulated tyrosinase. Artif. Cells Blood Substit. Immobil. Biotechnol. 30:533-546. an international journal.